高值创新药品过渡基金保障模式研究——基于英国癌症药物基金的实证分析  

Research on the interim fund for high-value innovative drugs:based on the empirical study of cancer drugs fund in england

作　　者：丁锦希[1] 吴逸飞[1] 李佳明 李伟[1] DING Jin-xi;WU Yi-fei;LI Jia-ming;LI Wei(School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing 211198,China)

机构地区：[1]中国药科大学国际医药商学院,南京211198

出　　处：《中国新药杂志》2020年第15期1691-1696,共6页Chinese Journal of New Drugs

基　　金：2017年国家人力资源和社会保障部项目《基本医疗保险药品支付标准制定及实施有关问题研究》、《基本医疗保险药品目录谈判准入方式设计》;2020年国家医疗保障局项目《药品医保支付标准制定规则研究》。

摘　　要：为平衡患者日益增长的用药需求与医保基金可持续之间的矛盾,部分国家开始探索高值创新药品过渡基金保障模式。本文通过英国癌症药物基金的实证研究,对其“分类筛选-补偿孵化-逾期分流”的关键机制进行了系统探讨,并深入思考了过渡基金与医保基金间的作用关系,以期为完善我国高值创新药品医疗保障体系提供借鉴。In order to balance the contradiction between patients'increasing demands for medication and the sustainable development of the medical insurance fund,several countries begin to explore the interim funds for high-value innovative drugs,which provide interim reimbursement for patients.Based on the empirical research,this article systematically discusses the key mechanism of Cancer Drugs Fund,and considers the relationship of interim fund and medical insurance fund in depth,so that provides a reference for the perfection of healthcare security system of high-value innovative drugs.

关 键 词：高值药品 过渡基金 医疗保障 医保准入 

分 类 号：R95[医药卫生—药学]